# Advances in Guillain-Barré Syndrome: Diagnosis, Biomarkers, and Management

Page: https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/advances-in-guillain-barr-syndrome-diagnosis-biomarkers-and-management
Text version: https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/advances-in-guillain-barr-syndrome-diagnosis-biomarkers-and-management.md
Podcast: [Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology](https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980)
Published: 2026-04-26T21:40:21+00:00
Episode link: https://podcasters.spotify.com/pod/show/amer-ghavanini/episodes/Advances-in-Guillain-Barr-Syndrome-Diagnosis--Biomarkers--and-Management-e3igkh6
Audio file: https://anchor.fm/s/ff5a3958/podcast/play/119082982/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-26%2Fc0784beb-8d25-c4fe-8585-37efc04901a8.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/advances-in-guillain-barr-syndrome-diagnosis-biomarkers-and-management
Duration seconds: 1252

## Resource

This comprehensive medical review examines recent developments in the diagnosis, pathophysiology, and management of Guillain-Barré syndrome (GBS) , an autoimmune disorder causing acute paralysis. The authors highlight a transition toward a molecular understanding of the disease, emphasizing the role of antecedent infections like Campylobacter jejuni and the identification of specific anti-ganglioside antibodies . While the text reviews established prognostic models and emerging fluid biomarkers like neurofilament light chain, it acknowledges that GBS remains primarily a clinical diagnosis. Regarding treatment, the source details updated 2023 guidelines that favor standard immunotherapies while explicitly advising against repeat immunoglobulin courses or corticosteroids. Finally, the authors evaluate the current clinical trial landscape , investigating novel but as-yet unproven targeted therapies such as complement inhibitors and neonatal Fc receptor blockades.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/advances-in-guillain-barr-syndrome-diagnosis-biomarkers-and-management/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/advances-in-guillain-barr-syndrome-diagnosis-biomarkers-and-management.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.